ALEXIOS MATRALIS
Chief Medicinal Chemist
Dr. Alexios N. Matralis holds a B.Sc. in Chemistry from the University of Patras and both an M.Sc. and Ph.D. in Medicinal Chemistry from the University of Athens. He has over fifteen years of research experience in the development of bioactive molecules targeting multifactorial human diseases such as atherosclerosis, type 2 diabetes, cancer, chronic inflammatory disorders, and malaria.
Following his Ph.D., he conducted postdoctoral research at McGill University in Montréal, Canada, where he developed a novel series of senescence-inducing agents for pancreatic cancer, which attracted interest from Merck for further development. In 2017, he joined GlaxoSmithKline as a senior researcher, where he contributed to the development of novel fast-acting antimalarial compounds, currently undergoing advanced preclinical studies. In 2018, Alexios joined BSRC “Alexander Fleming” as a Stavros Niarchos Research Fellow where he led research programs focused on small molecule drug discovery targeting fibrosis, cancer, and inflammatory diseases, including an Individual Research Grant from the Hellenic Foundation for Research and Innovation.
Since 2025, Alexios serves as Chief Medicinal Chemist at INOLYSIS, overseeing the design and development of novel therapeutics targeting fibroblast-driven pathologies.
OUR TEAM
Founder and President
_edited_edited_.jpg)
GEORGE KOLLIAS
Founder and President
George Kollias is Member of the Academy of Athens, Professor of Physiology at the Medical School, UoA, and Research Professor at the BSRC "Alexander Fleming". His lab provided proof of principle preclinical studies that led to the development of anti-TNF therapies for Rheumatoid arthritis. He has pioneered genetic approaches to study the function of cytokine signaling in animal models of human diseases and contributed knowledge on the molecular and cellular mechanisms driving chronic inflammation, autoimmunity and cancer. More recently, the lab made pioneering contributions to uncovering the pivotal role of fibroblasts in pathophysiology, instigating new therapeutic opportunities for chronic inflammatory and fibrotic diseases. His work has received 49K citations and an h-index of 100 (Source: Google Scholar). His laboratory is supported by several competitive grants from national sources and the European Commission, and has been awarded with two (2014, 2022) Advanced Grants from the European Research Council (ERC). GK developed the National Research Infrastructures Infrafrontier.GR/Phenotypos from BSRC Fleming, and pMedGR from the Medical School of Athens. In 2006 he founded Fleming’s first CRO biotech spinoff, Biomedcode Hellas SA, and in 2025 he founded INOLYSIS, which focuses on the development of therapeutics for fibrosis. He is Member of the European Molecular Biology Organization (EMBO). He was elected and served as President and Director of the Biomedical Sciences Research Center “Alexander Fleming” (2002-2010 & 2016-2020). In 2014, he was awarded the Carol-Nachman Award for Rheumatology. GK is Director of the International Graduate Program in "Molecular Biomedicine" running at the Medical School and BSRC Fleming.
DEEPAK BAROT
Chief Business Officer
DEEPAK BAROT
Chief Business Officer
Dr. Deepak Barot has 25+ years of pharmaceutical experience, with 15 years in global business development leadership across India, the US, Europe, and Asia-Pacific. He is an internationally recognized entrepreneur-scientist known for turning scientific capability into commercial growth. Previously, as Vice President of Preclinical Research at Athens LifeTech Park, he led scientific and commercial strategy for pharma and MedTech clients.
He held scientific and leadership roles at Zydus, Aurigene, Biocon–Bristol Myers Squibb, and Vanta Biosciences, and drove business development for US-based In Vitro ADMET Labs and Discovery Life Sciences. He advanced two products (one for a metabolic disorder and a digestive enzyme) from preclinical to market, helped build India’s first isolator-based rodent breeding facility for Harlan, established four preclinical CROs from greenfield to fully operational, revenue-generating businesses, and led 1,500+ preclinical studies.
He holds a PhD in Veterinary Pharmacology & Toxicology and a postgraduate certification in International Business Management. He serves on the Program Committee of the American Chemical Society (Div. of Chemical Toxicology), reviews for Drug Metabolism Reviews and Vet. World, sits on the Board of Studies at prestigious universities, and is an invited speaker and trainer at various international events.
PIYI PAPADAKI
Chief Operating Officer
PIYI PAPADAKI
Chief Operating Officer
Piyi Papadaki holds a B.Sc. in Chemistry from the University of Athens and an M.Sc. and Ph.D. in Molecular Biology from the Department of Biology at New York University (NYU), USA. She conducted postdoctoral research as a Marie Curie Fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 2008, she returned to Greece to join the group of George Kollias at BSRC Fleming, where she undertook the setup, management and coordination of major research, innovation, and infrastructure projects. From 2016 to 2020, she served as Head of the President’s Office and Grants Office at BSRC Fleming, overseeing organizational planning and cross-functional coordination across administrative and research units, while supporting executive decision-making and strategic development initiatives. She also provides consultancy to private-sector organizations, offering expertise in funding acquisition, human resources and intellectual property management, business development and commercialization strategy.
Since 2025, she serves as COO at INOLYSIS, where she supports strategic planning and operational execution of the company’s research and innovation activities.
MarCom Manager
ALEXANDRA BOUTLA
MarCom Manager
Alexandra Boutla holds a B.Sc. in Biology, an M.Sc. in Molecular Biology and Biomedicine, and a Ph.D. in Biology from the University of Crete. She conducted postdoctoral research at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Building on this scientific foundation, she transitioned into research management, accumulating more than 15 years of experience in the setup, management, and coordination of major EU and national research, innovation, and infrastructure projects, including FP7, Horizon 2020, IMI, and NSRF programs. Her key achievements include a pivotal role in establishing the Center of New Biotechnologies and Precision Medicine (pMedGR) at the Medical School of Athens and serving as the Administrative Coordinator for the International Bi-Institutional M.Sc. in Molecular Biomedicine.
Since 2025, she has served as Marketing & Communications Manager at INOLYSIS, where she supports the company’s strategic communication, dissemination activities, and stakeholder engagement, drawing on her strong scientific background and extensive experience in complex project coordination.
CHRISTINA CHANDRAS
Project & Data Officer
CHRISTINA CHANDRAS
Project & Data Management Officer
Christina Chandras holds a B.Sc. in Biochemistry from University College London and a Ph.D. in Biochemistry with honors from Royal Free & University College Medical School, University of London, where her research focused on reproductive endocrinology. She completed postdoctoral research at Children's Hospital, Harvard Medical School, USA, and the Biomedical Research Foundation Academy of Athens, studying hormone-regulated signaling pathways and neuroendocrine-immune interactions. In 2007 Christina joined BSRC “Alexander Fleming” and has since contributed to multidisciplinary research, first as Scientific Biocurator and Program Administrator, supporting EU-funded projects and database development, and later as Research Administration Coordinator and Database Specialist, managing data, laboratory operations, project coordination, and scientific communication, while also overseeing the development of HR Office administrative workflows and supporting research personnel.
Since 2025, she serves as Project & Data Management Officer at INOLYSIS, supporting project coordination, data analysis, and dissemination activities.
ALEXIOS MATRALIS
Chief Medicinal Chemist
ALEXIOS MATRALIS
Chief Medicinal Chemist
Alexios N. Matralis holds a B.Sc. in Chemistry from the University of Patras and both an M.Sc. and Ph.D. in Medicinal Chemistry from the University of Athens. He has over fifteen years of research experience in the development of bioactive molecules targeting multifactorial human diseases such as atherosclerosis, type 2 diabetes, cancer, chronic inflammatory disorders, and malaria.
Following his Ph.D., he conducted postdoctoral research at McGill University in Montréal, Canada, where he developed a novel series of senescence-inducing agents for pancreatic cancer, which attracted interest from Merck for further development. In 2017, he joined GlaxoSmithKline as a senior researcher, where he contributed to the development of novel fast-acting antimalarial compounds, currently undergoing advanced preclinical studies. In 2018, Alexios joined BSRC “Alexander Fleming” as a Stavros Niarchos Research Fellow where he led research programs focused on small molecule drug discovery targeting fibrosis, cancer, and inflammatory diseases, including an Individual Research Grant from the Hellenic Foundation for Research and Innovation.
Since 2025, Alexios serves as Chief Medicinal Chemist at INOLYSIS, overseeing the design and development of novel therapeutics targeting fibroblast-driven pathologies.
ANASTASIA MPAKALI
Lead Research Scientist
ANASTASIA MPAKALI
Lead Research Scientist
Anastasia Mpakali holds a B.Sc. in Biology and an M.Sc. and Ph.D. in Molecular Medicine from the National and Kapodistrian University of Athens, with her doctoral research conducted in collaboration with BSRC “Alexander Fleming”. She has extensive expertise in drug development, particularly in the design, screening, and mechanistic evaluation of small-molecule inhibitors targeting immune and neuroregulatory pathways.
With over 12 years of postdoctoral research experience, Anastasia has led impactful projects at the National Centre for Scientific Research “Demokritos”, including structural and functional studies of aminopeptidases (ERAP1/2, IRAP) and the development of nanomolar inhibitors for these targets. Her research, supported by competitive funding such as the HFRI/ELIDEK ARIA award, bridges atomic-resolution enzymology with translational drug design.
In 2024, she joined the Kollias Lab at BSRC “Alexander Fleming” as a postdoctoral fellow, leading the group’s translational R&D efforts to identify novel therapeutics against inflammation and fibrosis.
Since 2025, she serves as Lead Research Scientist at INOLYSIS, driving target validation, assay development, and screening strategies for the company’s fibroblast-targeted drug discovery pipeline.
FANI ROUMELIOTI
Senior Scientist
FANI ROUMELIOTI
Senior Scientist, Translational Research
Fani Roumelioti holds a B.Sc. in Biology, an M.Sc. in Applications of Biology in Medicine, and a Ph.D. in Medical Sciences from the National and Kapodistrian University of Athens. Her doctoral research, conducted at BSRC “Alexander Fleming” and supported by an IKY/SIEMENS scholarship, focused on the expression and functional role of regulatory RNAs in inflammatory polyarthritis.
With more than a decade of research experience, Fani specializes in inflammatory and fibrotic disease mechanisms, with a particular focus on fibroblast biology and chronic tissue inflammation. During her postdoctoral research, she investigated fibroblast heterogeneity across inflammatory arthritis, intestinal inflammation, and pulmonary fibrosis, using advanced disease models with molecular and cellular approaches.
Her expertise includes preclinical disease modelling, primary fibroblast culture, gene-expression modulation using siRNA, shRNA, and CRISPR-Cas, transcriptomics, single-cell and spatial transcriptomics, multiplex imaging, and FACS. She also has experience in chemical biology and drug discovery, including click chemistry and CETSA for target identification and validation.
Since 2026, Fani has been part of INOLYSIS, where she contributes her expertise in fibroblast biology and disease modelling to the discovery and validation of therapeutic targets for inflammatory and fibrotic diseases.
VASILIKI MAVRIKAKI
Scientist, Medicinal Chemistry
VASSILIKI MAVRIKAKI
Scientist, Medicinal Chemistry
Vassiliki Mavrikaki holds a B.Sc. in Chemistry, an M.Sc. in Organic Synthesis, and a Ph.D. in Medicinal Chemistry from the National and Kapodistrian University of Athens, with her doctoral research conducted in collaboration with the Biomedical Sciences Research Center “Alexander Fleming”. Her Ph.D. focused on the development of bioactive compounds targeting pathogenic fibroblast activation in chronic inflammatory diseases.
Her research background encompasses medicinal and synthetic organic chemistry, including the design, synthesis, and structural characterization of small molecules, and their biological evaluation. Moreover, she has expertise in in vitro
target identification of bioactive compounds using click chemistry and chemoproteomics approaches, as well as in vivo pharmacokinetics studies. Her work has contributed to first-in-class HYOU1 inhibitors suppressing fibroblast-driven pathology.
Since 2024, Vasiliki has worked as a postdoctoral researcher in the Matralis Lab, designing and synthesizing novel therapeutics targeting fibrosis. In 2026, she joined INOLYSIS as a Scientist in Medicinal Chemistry, contributing to the discovery and development of small-molecule antifibrotic therapies.
IOANNA KOTOUZA
Research Scientist
IOANNA KOTOUZA
Scientist, Cellular Assays & Profiling
Ioanna Kotouza holds a B.Sc. in Biology, specializing in Molecular Biology and Biotechnology, from the University of Crete, and an M.Sc. in Biological Sciences from the University of Cologne, with a focus on mechanisms of aging and aging-associated diseases. During her academic training, she conducted research on BCMA expression and trafficking in cancer cells and investigated the secretome of ferroptotic cancer cells and its role in inflammatory responses. She subsequently joined F. Hoffmann-La Roche AG in Basel, where she worked in ADME. During her first year, she focused on the research and development of an in vitro cellular assay to characterize biologics clearance and Target-Mediated Drug Disposition (TMDD), centered on high-content imaging. Following its development and optimization, the assay was implemented to support the assessment of biologics under development within the Roche portfolio. She also contributed to other ADME activities, including high-throughput immunoassays, laboratory automation workflows, and analytical assays for the characterization of complex biologics.
Ioanna joined INOLYSIS in 2026, where she contributed to the development and optimization of cellular assays, transcriptomic and metabolic analyses of candidate bioactive molecules, and laboratory approaches for evaluating their biological activity and formulation, supporting translational research and drug discovery activities.